PMID- 28857483
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20220408
IS  - 1755-3768 (Electronic)
IS  - 1755-375X (Linking)
VI  - 96
IP  - 7
DP  - 2018 Nov
TI  - Intravitreal gas for symptomatic vitreomacular adhesion: a synthesis of the 
      literature.
PG  - 685-691
LID - 10.1111/aos.13547 [doi]
AB  - Symptomatic vitreomacular adhesion (sVMA) is defined as visual loss secondary to 
      foveal damage from vitreomacular traction (VMT) and includes isolated VMT, 
      impending macular hole (MH), and full-thickness MH with persisting vitreous 
      attachment. Management options include pars plana vitrectomy (PPV), intravitreal 
      ocriplasmin, intravitreal gas injection or observation. This synthesis of the 
      literature aimed to assess the safety and efficacy of intravitreal gas for sVMA. 
      Articles describing patients with VMT or MH treated with intravitreal expansile 
      gas were selected by systematic literature review using MEDLINE, EMBASE, and the 
      Cochrane Database of Controlled Trials (CENTRAL) up to September 2016. The main 
      outcomes at 1 month and final review were logarithm of the minimum angle of 
      resolution (logMAR) visual acuity (VA), anatomical success (absence of both VMT 
      and MH, without PPV) and adverse events (AEs). The intended comparator was 
      observation. Nine of 106 identified articles were eligible, and none were 
      randomized controlled trials. The mean VA of 91 eyes improved from 0.55 (Snellen 
      equivalent 6/21) to 0.48 (6/18) logMAR at 1 month and to 0.35 (6/13) logMAR at 
      final review. The mean VA at final review, prior to a vitrectomy, was 0.42 
      (6/16). Anatomic success was 48% at 1 month and 57% at final review. The reported 
      AEs comprised retinal detachment in two highly myopic eyes. Intravitreal gas 
      injection can relieve sVMA. Larger controlled studies are needed to determine 
      safety and efficacy relative to observation, ocriplasmin, or vitrectomy.
CI  - (c) 2017 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & 
      Sons Ltd.
FAU - Neffendorf, James E
AU  - Neffendorf JE
AUID- ORCID: 0000-0001-6342-7157
AD  - Oxford Eye Hospital, John Radcliffe Hospital, Oxford, UK.
AD  - King's College London, London, UK.
FAU - Simpson, Andrew R H
AU  - Simpson ARH
AD  - King's College London, London, UK.
FAU - Steel, David H W
AU  - Steel DHW
AD  - Sunderland Eye Infirmary, Sunderland, UK.
AD  - Institute of Genetic Medicine, Newcastle University, Newcastle, UK.
FAU - Desai, Riti
AU  - Desai R
AD  - King's College London, London, UK.
AD  - King's College Hospital, London, UK.
FAU - McHugh, Dominic A
AU  - McHugh DA
AD  - King's College Hospital, London, UK.
FAU - Pringle, Edward
AU  - Pringle E
AD  - King's College Hospital, London, UK.
FAU - Jackson, Timothy L
AU  - Jackson TL
AD  - King's College London, London, UK.
AD  - King's College Hospital, London, UK.
LA  - eng
GR  - Novartis/
GR  - Alcon/
PT  - Journal Article
PT  - Review
DEP - 20170831
PL  - England
TA  - Acta Ophthalmol
JT  - Acta ophthalmologica
JID - 101468102
RN  - 0 (Fluorocarbons)
RN  - CK0N3WH0SR (perflutren)
RN  - WS7LR3I1D6 (Sulfur Hexafluoride)
SB  - IM
MH  - Endotamponade/*methods
MH  - Fluorocarbons/*administration & dosage
MH  - Humans
MH  - Intravitreal Injections
MH  - Prone Position
MH  - Retinal Diseases/*therapy
MH  - Sulfur Hexafluoride/*administration & dosage
MH  - Vitreous Detachment/*therapy
OTO - NOTNLM
OT  - gas
OT  - macula
OT  - vitreomacular adhesion
OT  - vitreomacular traction
OT  - vitreous
EDAT- 2017/09/01 06:00
MHDA- 2018/12/12 06:00
CRDT- 2017/09/01 06:00
PHST- 2017/03/02 00:00 [received]
PHST- 2017/06/30 00:00 [accepted]
PHST- 2017/09/01 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2017/09/01 06:00 [entrez]
AID - 10.1111/aos.13547 [doi]
PST - ppublish
SO  - Acta Ophthalmol. 2018 Nov;96(7):685-691. doi: 10.1111/aos.13547. Epub 2017 Aug 
      31.